Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots

The Anthos Therapeutics acquisition represents a homecoming for its drug abelacimab, which originated in Novartis’s labs. The antibody offers the potential to prevent blood clots without the bleeding risks associated with currently available anticoagulants. The post Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots appeared first on MedCity News.

Read More

Man and Machine: A New Age for Medicine

By MIKE MAGEE “As machines become more intelligent and can performance more sophisticated functions, a new relationship between human and automation is dawning. This relationship is moving from master-servant to teammates…” NASA Langley Research Center/2019 “DeepSeek’s Breakthrough Sparks National Pride in China,” screamed the Wall Street Journal headline last week. In the age of Trump’s…

Read More